Company intelligence / Profile preview

SPOBY

Oxford, England, United Kingdomprettylittleliars.fandom.com ↗

Ownership: Private
Development stage: Other

Overview

SpyBiotech has completed enrollment in a Phase 1 clinical trial of its lead vaccine candidate SPYVLP01 targeting human cytomegalovirus. The company leverages its proprietary protein superglue platform to develop vaccines with improved efficacy and speed. No published clinical results yet; the program remains in early-stage human testing as of July 2024.

Therapeutic areas: OtherOncologyInfectious Diseases
Modalities: VaccineProteinLive biotherapeutic product therapy (platform enables various vaccine modalities)
Industry: Biotech

Beyond the preview

Go deeper on SPOBY.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPOBY.

Explore the full profile